A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease

Biomedical and Life Sciences

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease. / Foulds, Penny ; Diggle, Peter; Mitchell, John Douglas et al.
In: Scientific Reports, Vol. 3, 2540, 29.08.2013.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Foulds, P , Diggle, P, Mitchell, JD, Parker, A, Hasegawa, M, Masuda-Suzukake, M, Mann, DMA & Allsop, D 2013, 'A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease', Scientific Reports, vol. 3, 2540. https://doi.org/10.1038/srep02540

APA

Foulds, P., Diggle, P., Mitchell, J. D., Parker, A., Hasegawa, M., Masuda-Suzukake, M., Mann, D. M. A., & Allsop, D. (2013). A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease. Scientific Reports, 3, Article 2540. https://doi.org/10.1038/srep02540

Vancouver

Foulds P , Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M et al. A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease. Scientific Reports. 2013 Aug 29;3:2540. doi: 10.1038/srep02540

Author

Foulds, Penny ; Diggle, Peter ; Mitchell, John Douglas et al. / A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease. In: Scientific Reports. 2013 ; Vol. 3.

Bibtex

@article{91008ca5d7cc4babba87364c191721ed,

title = "A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson{\textquoteright}s disease",

abstract = "There have been no longitudinal studies on α-synuclein as a potential biomarker for the progression of Parkinson{\textquoteright}s disease (PD). Here, blood plasma {\textquoteleft}total α-synuclein{\textquoteright} and {\textquoteleft}Ser-129 phosphorylated α-synuclein{\textquoteright} were assayed at 4–6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total α-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p = 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated α-synuclein, but not of total α-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p = 0.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total α-synuclein could act as a surrogate marker for the progression of PD.",

keywords = "Parkinson's disease, biomarker, longitudinal cohort study",

author = "Penny Foulds and Peter Diggle and Mitchell, {John Douglas} and Angela Parker and Masato Hasegawa and Masami Masuda-Suzukake and Mann, {David M. A.} and David Allsop",

year = "2013",

month = aug,

day = "29",

doi = "10.1038/srep02540",

language = "English",

volume = "3",

journal = "Scientific Reports",

publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson’s disease

AU - Foulds, Penny

AU - Diggle, Peter

AU - Mitchell, John Douglas

AU - Parker, Angela

AU - Hasegawa, Masato

AU - Masuda-Suzukake, Masami

AU - Mann, David M. A.

AU - Allsop, David

PY - 2013/8/29

Y1 - 2013/8/29

N2 - There have been no longitudinal studies on α-synuclein as a potential biomarker for the progression of Parkinson’s disease (PD). Here, blood plasma ‘total α-synuclein’ and ‘Ser-129 phosphorylated α-synuclein’ were assayed at 4–6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total α-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p = 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated α-synuclein, but not of total α-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p = 0.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total α-synuclein could act as a surrogate marker for the progression of PD.

AB - There have been no longitudinal studies on α-synuclein as a potential biomarker for the progression of Parkinson’s disease (PD). Here, blood plasma ‘total α-synuclein’ and ‘Ser-129 phosphorylated α-synuclein’ were assayed at 4–6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total α-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p = 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated α-synuclein, but not of total α-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p = 0.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total α-synuclein could act as a surrogate marker for the progression of PD.

KW - Parkinson's disease

KW - biomarker

KW - longitudinal cohort study

U2 - 10.1038/srep02540

DO - 10.1038/srep02540

M3 - Journal article

VL - 3

JO - Scientific Reports

JF - Scientific Reports

M1 - 2540

ER -

Research

Associated organisational unit

Links

Text available via DOI:

Keywords